Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
262 studies found for:    Recruiting | NIDDK
Show Display Options
Rank Status Study
1 Recruiting Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)
Condition: Type 1 Diabetes
Interventions: Drug: 67.5 mg oral insulin crystals daily;   Drug: 500mg oral insulin crystals every other week
2 Recruiting Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Prospective Observational Cohort Study Protocol
Condition: Lower Urinary Tract Symptoms
Interventions: Other: None-observational;   Procedure: Magnetic Resonance Imaging (MRI);   Other: Multimodal Automated Sensory Testing System;   Other: Auditory Sensitivity Test
3 Recruiting Blood Flow and Vascular Function in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Acute (1 hour) Sildenafil;   Drug: Sub-Chronic (4 weeks) Sildenafil;   Drug: Placebo
4 Recruiting CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
Conditions: Abnormal Glucose Tolerance;   Type 1 Diabetes
Interventions: Drug: CTLA4-Ig (Abatacept);   Drug: Placebo
5 Recruiting Gastroparesis Registry 2
Conditions: Gastroparesis;   Diabetic Gastroparesis;   Idiopathic Gastroparesis
Intervention:
6 Recruiting Longitudinal Study of Mitochondrial Hepatopathies
Conditions: Acute Liver Failure,;   Mitochondrial Diseases;   End Stage Liver Disease,;   Respiratory Chain Deficiencies, Mitochondrial;   Disorder of Fatty Acid Oxidation
Intervention:
7 Recruiting NAFLD Pediatric Database 2
Condition: Liver Disease
Intervention:
8 Recruiting Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
Conditions: Autoantibody Positive;   Non-diabetic Relatives at Risk for Type 1 Diabetes;   High Risk;   Impaired Glucose Tolerance
Intervention: Drug: Teplizumab
9 Recruiting Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Condition: Liver Disease
Intervention:
10 Recruiting Evaluating the Genetic Causes and Progression of Cholestatic Liver Diseases (LOGIC)
Conditions: Liver Diseases;   Alagille Syndrome;   Alpha 1-Antitrypsin Deficiency
Intervention:
11 Recruiting Biliary Atresia Study in Infants and Children
Condition: Biliary Atresia
Intervention:
12 Recruiting Familial Barrett's Esophagus
Conditions: Barrett's Esophagus;   Esophageal Neoplasm
Intervention:
13 Recruiting Pathway to Prevention Study
Condition: Diabetes Mellitus, Type 1
Intervention:
14 Recruiting Low-Dose Leptin and the Formerly-Obese
Condition: Obesity
Interventions: Drug: Leptin;   Behavioral: Dietary modification;   Drug: T3 repletion
15 Recruiting Biliary Atresia Research Consortium
Conditions: Biliary Atresia;   Cholestasis
Intervention:
16 Recruiting Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
Condition: Lipodystrophy
Interventions: Drug: ISIS 304801;   Drug: Placebo
17 Recruiting A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
Condition: Kidney Disease
Intervention: Drug: N-acetyl
18 Recruiting Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Conditions: Liver Disease;   Fatty Liver
Intervention:
19 Recruiting Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Condition: Hepatitis D
Interventions: Drug: Lonafarnib;   Drug: Ritonavir;   Other: Placebo
20 Recruiting Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: GS-5816

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.